Strategies to address hypoxia in NSCLC encompass hypoxia molecular target inhibitors (such as HIF-1α inhibitors), hypoxia-activated prodrugs (including misonidazole and nimorazole), radiation sensitizers for hypoxic cells (like tirapazamine), agents that enhance oxygen delivery (for instance, efaproxiral), and medications that diminish oxygen consumption (such as metformin) [106]. Here, HIF1A is linked to non-small cell lung carcinoma.